News

1 to 9 of 82 results

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Report: Japanese pharma market edging towards $80 Billion by 2020

Report: Japanese pharma market edging towards $80 Billion by 2020

26-02-2015

Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of…

Bristol-Myers SquibbGlobalDataJapanMarkets & MarketingPharmaceutical

Moderate growth forecast for colorectal cancer drug market

22-01-2015

The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion…

AvastinBayerBristol-Myers SquibbErbituxGlobalMarkets & MarketingMerck KGaAOncologyPharmaceuticalRocheStivarga

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

08-10-2014

Bristol-Myers Squibb has decided that it will not pursue US Food and Drug Administration approval of…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirGenotypeGilead SciencesMarkets & MarketingPharmaceuticalRegulationSovaldiUnited StatesUS Food and Drug AdministrationUSA

1 to 9 of 82 results

COMPANY SPOTLIGHT

Menarini

Back to top